Lynda Chin

See the following -

Experts Say IBM Watson’s Flaws are Rooted in Data Collection and Interoperability

Evan Sweeney | Fierce Healthcare | September 6, 2017

Despite being backed by a significant budget and the marketing power of a major technology company, IBM Watson appears to be falling short of expectations when it comes to revolutionizing cancer care. The shortcomings of IBM’s premier artificial intelligence system—made famous by its appearance on Jeopardy in 2011 and later co-pted to provide support for oncologists—are linked to a number of factors, according to an in-depth investigation by Stat that included interviews with doctors and artificial intelligence experts from around the world...

Read More »

IBM Pitched Its Watson Supercomputer as a Revolution in Cancer Care. It’s Nowhere Close

Casey Ross | STAT | September 5, 2017

It was an audacious undertaking, even for one of the most storied American companies: With a single machine, IBM would tackle humanity’s most vexing diseases and revolutionize medicine. Breathlessly promoting its signature brand — Watson — IBM sought to capture the world’s imagination, and it quickly zeroed in on a high-profile target: cancer. But three years after IBM began selling Watson to recommend the best cancer treatments to doctors around the world, a STAT investigation has found that the supercomputer isn’t living up to the lofty expectations IBM created for it. It is still struggling with the basic step of learning about different forms of cancer...

Read More »